GLP-1 medications like Ozempic, Wegovy and Mounjaro are increasingly being used across Australia for weight loss, type 2 diabetes, insulin resistance and PCOS management
Trizio, M
By Indication (Type-2 Diabetes, Obesity/Weight Management, and Other Emerging Indications): The type 2 diabetes segment is projected to reach USD 169.62 billion by 2033, supported by rising global diabetes prevalence, established clinical efficacy of GLP-1 therapies, and continued physician preference for managing blood glucose and metabolic risks
These symptoms may indicate that your current dose is too high for your body, or that GLP-1 therapy needs adjustmentsuch as spacing injections further apart, reducing your starting dose, or exploring alternative compounds like oral semaglutide or microdose protocols
doi: 10.1016/j.immuni.2022.05.014